. 2014 Jun 13;5(12):4529–4542. doi: 10.18632/oncotarget.2102

Table 1. Icotinib reverse the ABCG2-mediated drug resistance in drug selected resistant NSCLC cells.

	IC₅₀ ± SD^a (μM)
Compounds	A549	(RF)^b	NCI-H460	(RF)^b	NCI-H460/MX20	(RF)^b
Mitoxantrone (μM)	0.2853 ± 0.0214	1	0.0668 ± 0.0033	1.0	5.0837 ± 0.7542	76.0
+ Icotinib 1.0 μM	0.2269 ± 0.0193	0.8	0.0354 ± 0.0028^*	0.5	1.9336 ± 0.1121^*	28.9
+ Icotinib 5.0 μM	0.1695 ± 0.0102^*	0.6	0.0314 ± 0.0022^*	0.5	0.3559 ± 0.0249^*	5.3
+ FTC 5.0 μM	0.1858 ± 0.0167^*	0.7	0.0300 ± 0.0023^*	0.4	0.3316 ± 0.0265^*	5.0
SN-38 (μM)	0.6251 ± 0.0313	1.0	0.0707 ± 0.0035	1.0	8.1222 ± 1.006	114.9
+ Icotinib 1.0 μM	0.2482 ± 0.0199^*	0.4	0.0202 ± 0.0016^*	0.3	2.6770 ± 0.1553^*	37.8
+ Icotinib 5.0 μM	0.1717 ± 0.0120^*	0.3	0.0150 ± 0.0011^*	0.2	0.3271 ± 0.0229^*	4.6
+ FTC 5.0 μM	0.1752 ± 0.0131^*	0.3	0.0166 ± 0.0012^*	0.2	0.3126 ± 0.0250^*	4.4
Topotecan (μM)	1.4551 ± 0.1237	1.0	0.0490 ± 0.0042	1.0	4.8721 ± 0.4141	99.4
+ Icotinib 1.0 μM	0.9458 ± 0.0851^*	0.7	0.0226 ± 0.0020^*	0.5	0.1261 ± 0.0113^*	2.6
+ Icotinib 5.0 μM	0.9313 ± 0.0931^*	0.6	0.0196 ± 0.0019^*	0.4	0.0598 ± 0.0060^*	1.2
+ FTC 5.0 μM	1.0186 ± 0.0866^*	0.7	0.0194 ± 0.0016^*	0.4	0.0639 ± 0.0054^*	1.3
Cisplatin (μM)	2.7677 ± 0.2214	1.0	1.2692 ± 0.1015	1.0	1.3200 ± 0.1056	1.0
+ Icotinib 5.0 μM	2.9831 ± 0.1492	1.1	1.2727 ± 0.0636	1.0	1.2012 ± 0.0841	0.9
+ FTC 5.0 μM	3.2343 ± 0.2264	1.2	1.2017 ± 0.0841	0.9	1.2540 ± 0.0627	1.0

IC₅₀ values are represented the mean ± standard deviation (SD).

Resistance fold (RF) was calculated by the IC₅₀ values for different substrates, and cisplatin of NCI-H460/MX20 cells, divided by the IC₅₀ values for the respective control without the reversing agents, or the resistant cell lines in the presence or absence of Icotinib or FTC, divided by the IC₅₀ values for different substrates, and cisplatin of respective control without the reversing agents.

. P < 0.05, versus the control group